Proteins in the epidermal growth factor receptor (EGFR) family play key roles in cell proliferation, differentiation, and tumorigenesis. Among all EGFR family proteins, ErbB2 is known to be overexpressed in a wide spectrum of cancers, including breast cancer, gastric cancer, nonsmall cell lung carcinoma, and ovarian cancer [1, 2] . Amplification of ErbB2 triggers strong tumorigenic signals, such as activation of the PI3K/AKT pathways, through the dimerization of ErbB1 and ErbB3 [1] . ErbB2 signaling also protects cells that are exposed to apoptosis-inducing molecules such as 5 0 -FU. In addition, overexpression of ErbB2 in tumor cells promotes transformation into a malignant tumor, resulting in poor clinical outcomes in cancer patients [2] . Tyrosine kinase inhibitors such as afatinib and lapatinib have been developed and used for treatment of patients with cancer cells that overexpress ErbB2 [3] . The monoclonal anti-ErbB2 antibody trastuzumab is another anticancer drug for breast cancer Abbreviations EGFR, epidermal growth factor receptor; HMGB1, high mobility group 1; MTD, mitochondrial targeting domain; PI, propidium iodide.
overexpressing ErbB2 [1] . These inhibitors have demonstrated significantly improved outcomes for treatment of cancer patients, indicating that ErbB2 is a key target for therapy [4] [5] [6] . However, these anticancer drugs cause mutations in ErbB2 in tumor cells that interfere with the binding of anticancer drugs to ErbB2, and these tumor cells become drug-resistant tumor cells [1, 3, 7] . Thus, it is necessary to develop a novel anticancer drug that is not affected by ErbB2 mutation or resistance [2, 8] .
Many tumor-homing peptides provide a tool to selectively deliver killing materials to tumor cells [9] . KCCYSL has been identified as an ErbB2-targeting peptide by bacteriophage display screening [10] . It has also been adapted for use as a diagnostic agent for breast carcinomas and ovarian carcinomas and to deliver anticancer drugs to ErbB2-expressing cells by conjugating KCCYSL to imaging agents and anticancer agents, respectively [11, 12] .
The mitochondrial targeting domain (MTD), consisting of 10 amino acids derived from the C terminus of the pronecrotic peptide Noxa, directly targets the mitochondria in cells and leads to necrosis when conjugated to cell-penetrating peptides; however, it does not induce necrosis outside of cells due to the lack of cell permeability of the MTD [13, 14] . In our previous study, we showed that TU17:MTD, in which the MTD is fused to the NRP-1-targeting motif (RPARPAR), effectively inhibited tumor growth without side effects [15] .
In this study, we developed a novel peptide that targets ErbB2-overexpressing cells and induces necrosis by generating a hybrid peptide of the MTD and KCCYSL. We found that this molecule, termed KWSY:MTD, induces cell death by targeting ErbB2-expressing tumor cells in vitro and in vivo.
Materials and methods

Peptide synthesis
All synthesized peptides were purchased from GenScript (Piscataway, NJ, USA) or A&PEP (Chungbuk, Korea). All peptides were purified by rapid reverse phase-HPLC to homogeneity (i.e., > 90%) and evaluated by mass spectrometry. The peptides were dissolved in water or 50% DMSO. Peptide sequences used in this study are presented in Fig. 1C .
Antibodies and recombinant proteins
Anti-ErbB2 (Cat. #2165S) and anti-MAPK (Cat. #4376S) antibodies were purchased from Cell Signaling Technology (Danvers, MA, USA). Anti-HMGB1 antibody (Cat. #. ab18256) were purchased from Abcam (Cambridge, UK). Recombinant EGF protein was purchased from Sigma-Aldrich Korea (Cat. #E9644, Seoul, Korea). Recombinant 6xHis-profilin protein was purified in our laboratory using Ni-nitrilotriacetic acid agarose column (Cat. #30230, Qiagen, Hilden, Germany). 
Cell viability assay
HMGB1 release
Supernatants collected from 4T1 cells treated with peptides were precipitated with 4 volumes of À20°C 10% TCA by centrifugation, followed by a wash of the pellets with 20 mM DTT in acetone at À20°C. HMGB1 was detected by western blot analysis with the anti-HMGB1 antibody (Abcam Cat. #. ab18256, Cambridge, UK).
Isolation of mitochondria
Mitochondria were isolated from 6-week-old BalB/C mouse livers as described previously [16] . Briefly, mouse livers were minced in washing buffer (250 mM mannitol, 70 mM sucrose, 0.5 mM EGTA, 5 mM HEPES [pH7.4], 0.1 mM PMSF, and 4 lM Rotenone) and homogenized with the Teflon PotterElvehjem tissue grinder (Sigma-Aldrich Korea, Seoul, Korea). The homogenate was centrifuged at 1000 9 g for 10 min at 4°C. The supernatant was centrifuged at 10 000 9 g for 10 min at 4°C. The pellet was washed twice with regeneration buffer (250 mM sucrose, 10 mM HEPES [pH 7.4], 5 mM sodium succinate, 25 lM EGTA, 2 mM potassium phosphate, 0.1 mM PMSF, and 4 lM Rotenone). The final pellet was resuspended in regeneration buffer for further experiments.
Mouse tumor models
Animal experiments were performed in accordance with the guidelines of Chosun University Institutional Animal Care and /SzJ mice (6-week old) purchased from The Jackson Laboratory (Bar Harbor, ME, USA). Tumor, liver, and kidney tissues were collected on the last day of observation and were processed for hematoxylin and eosin staining.
Statistical analysis
Statistical data are expressed as mean AE SD. Statistical analysis was carried out with ANOVA to evaluate the difference between two groups. Statistical significance was accepted for P values < 0.05.
Results
Design of ErbB2-targeting necrosis-inducing peptides
To develop an ErbB2-targeting necrosis-inducing peptide, the MTD was fused to an ErbB2-targeting motif (KCCYSL) to selectively deliver the necrosis-inducing peptide to ErbB2-expressing cells; this fused peptide was named KCCYSL:MTD (Fig. 1A) . When the A431 cell line, an ErbB2-expressing line (Fig. 2B) , was treated with KCCYSL:MTD, the viability of A431 was decreased in a dose-dependent manner in the range from 10 to 40 lM. However, KCCYSL alone and the MTD alone showed no changes in the viability in A431 cells (Fig. 1B ). Although KCCYSL:MTD exhibited killing activity in A431 cells, the cytotoxicity of KCCYSL:MTD was insufficient. Moreover, KCCYSL: MTD has low solubility in water and high viscosity, making absorption in biological systems difficult. Thus, we modified the ErbB2-targeting motif to enhance cell killing activity and to improve the physical properties of solubility and viscosity. To screen for the best hybrid peptide with regard to killing activity and targeting, two ErbB2 overexpressing cancer cell lines, FaDu and MCF7 (Fig. 2B ), were treated with peptides (Fig. 1C,D) . KCCYSL:MTD exhibited no killing effect in FaDu and MCF7 cells, indicating that the combination of KCCYSL and the MTD may inhibit the targeting ability of KCCYSL to the ErbB2 protein. Two modified peptides, KWSY and KSWY, combined with the MTD showed the best killing activities in both FaDu and MCF7 cells, although KWCYS, KCWY, and KSSYSL with the MTD all showed some killing activities in MCF7 cells (Fig. 1C,D) .
KWSY:MTD kills ErbB2-expressing cancer cells
To identify the optimal peptide from the set of modified hybrid peptides, tumor cells that display high or low expression of ErbB2 were treated with peptides ( Fig. 2A) . KWCYS:MTD and KWSY:MTD (range of 20-40 lM) were sufficient to induce cell death in tumor cells with high expression of ErbB2 such as the A431, 293, and A549 cell lines, whereas these peptides did not induce cell death in cells with low expression of ErbB2 such as the U373MG, CT26, and HePa-1c1c7 cell lines. The killing activity of the peptides in cells derived from mouse breast cancer was also tested to investigate whether the peptide can selectively kill ErbB2-expressing mouse cell lines. KWSY:MTD effectively killed the ErbB2-high-expressing mouse breast cancer cell 4T1, but KCCYSL:MTD did not kill when used at 20-40 lM (Fig. 2A) . To test whether peptides selectively kill cancer cells and not normal cells, isolated normal splenocytes from mice were treated with the peptides. As shown in Figure 2A , KWSY:MTD did not kill splenocytes even at higher concentrations (> 80 lM), whereas KCCYSL:MTD and KWCYS:MTD exhibited some killing activity when used at 40-80 lM. The IC 50 (the concentration that induces 50% inhibition) of the KWSY:MTD peptide for normal splenocytes was 20-fold higher than that for Jurkat cells (Fig. 2B) .
Together, these results suggest that KWSY:MTD has stronger killing activity in ErbB2-high-expressing tumor cells rather than in normal cells.
Blocking EGFR inhibits KWSY:MTD-induced killing
To test the specificity of KWSY:MTD for targeting ErbB2, an anti-ErbB2 antibody was used to compete for binding to ErbB2 with KWSY:MTD, which is expected to decrease the killing activity of KWSY: MTD. Indeed, when FaDu cells pretreated with an anti-ErbB2 antibody were treated with KWSY:MTD, the level of cell death was greatly inhibited. However, the control antibody (anti-MAPK antibody) also mildly blocked the cell death induced by KWSY:MTD (Fig. 3A,B) . Moreover, KWSY:MTD-induced cell death was inhibited in EGF-pretreated cells compared to that in control protein (recombinant 6xHis profilin)-treated cells (Fig. 3A) . These results suggest that KWSY:MTD-induced cell death is dependent on the level of ErbB2 expression in tumor cells and that KWSY:MTD is binding to ErbB2.
KWSY:MTD induces necrosis in tumor cells
Our previous studies have demonstrated that TU17: MTD and R8:MTD cause necrosis in cancer cells; thus, we expected that KWSY:MTD would also induce necrosis due to the necrosis-inducing motif, MTD [13, 15] . High mobility group 1 (HMGB1) is a protein present in the nucleus as a chromatin-binding protein and is released outside the cell when necrotic cell death such as nonprogrammed cell death is induced. The release of HMGB1 outside the cell is a biochemical indicator of necrotic cell death [15, 17] . Necrotic bodies were evidently formed in less than 10 min after 20 lM of KWSY:MTD treatment (Fig. 3B) , and many PI-positive 4T1 cells were observed in response to KWSY:MTD; however, a low level of PI-positive 4T1 cells was observed in response to KCCYSL alone, the MTD alone, and KCCYSL: MTD (Fig. 4A,B) . HMGB1 was released into media in response to KWSY:MTD, supporting the idea that KWSY:MTD is a necrosis-inducing peptide (Fig. 4C) . However, the reason why KWSY:MTD released more HMGB1 protein outside the cell than KWCYS:MTD is not clear, although KWCYS:MTD caused more PI-stained cells than KWSY:MTD.
The opening of the mitochondrial permeability transition pore (mPTP) is known to be an important event in apoptosis or necrosis. When the mPTP is opened, the mitochondrial matrix swells, and the mitochondrial membrane integrity is damaged. Death factors in the mitochondrial matrix or intermembrane space are released into the cytosol, leading to rupture of the cell membrane [14, [18] [19] [20] [21] . As shown in Figure 4D , the swelling of the mitochondrial matrix was monitored through changes in optical density at 540 nm in isolated mouse mitochondria. Consistent with previous reports [22, 23] , calcium ions significantly induced mPTP opening, which was blocked by cyclosporine A (CsA). KWSY: MTD and KWCYS:MTD decreased the optical density of isolated mitochondria at 540 nm despite the low degree of mPTP opening compared to that induced by calcium ions; however, KCCYSL alone and the MTD alone did not change the optical density at 540 nm. These results indicate that KWSY:MTD and KWCYS: MTD open mPTP, causing necrosis in tumor cells.
In vivo antitumor activity of KWSY:MTD in ErbB2 overexpressing cancer
To assess the ErbB2-specific anticancer effects of KWSY:MTD on tumor growth in a syngeneic tumor model, CT26 cells (an ErbB2-low-expressing cell line) and 4T1 cells (an ErbB2-high-expressing cell line) were used to generate tumor tissues in BalB/C mouse. We expected that the killing activity of KWSY:MTD in tumor tissues bearing CT26 cells would be minimal, whereas KWSY:MTD would exhibit robust killing activity in tumor tissues bearing 4T1 cells. Indeed, inhibition of tumor growth by KWSY:MTD in tumor tissue bearing CT26 cells was not seen when KWSY: MTD was intravenously administrated into mice via the tail vein (Fig. 5A ), whereas KWSY:MTD exhibited growth suppression in tumor tissue bearing 4T1 cells (Fig. 5B) . ) for 1 h were treated with KWSY:MTD (20 lM) for an additional 1 h. Cell viability was measured by the MTS assay (A), and cell images were taken using inverted optical microscopy (B). **P < 0.05, ***P < 0.001.
The FaDu cell line is a human pharynx squamous cell carcinoma, which has higher expression levels of ErbB2 (Fig. 2B) , and FaDu cells were sensitive to KWSY:MTD at 10-20 lM (Fig. 1C) . To examine the anticancer effects of KWSY:MTD in a xenograft model using FaDu cells, tumor tissues of FaDu cells were formed on the backs of NOD-scidIL2Rg null mice that lack mature T cells, B cells, and NK cells [24] . The killing activity of KWSY:MTD in tumor tissues bearing FaDu cells was significant (Fig. 5C) , and was evident in H&E staining (Fig. 5D ). In addition, H&E staining of kidney and liver tissues of KWSY:MTDtreated mice or nontreated mice exhibited no damage. Together, these results indicate that KWSY:MTD targets and kills the tumor cells expressing ErbB2 but not noncancerous cells in the liver and kidney.
Discussion
In this study, we developed a novel ErbB2-targeting peptide combined with the MTD, KWSY:MTD. We found that KWSY:MTD kills the ErbB2-high-expressing tumor cells by necrosis, but shows limited killing activity in noncancerous cells or ErbB2-low-expressing tumor cells in vivo and in vitro.
The KWSY sequence was, in this study, modified from KCCYSL, a well-known ErbB2-targeting motif. KCCYSL was identified as an ErbB2-binding peptide through phage-display screening [25] , and was used for cancer imaging agents and delivery tools to target ErbB2-expressing cells [10] [11] [12] 26] . In this study, direct coupling of KCCYSL with the MTD was not satisfactory because high amounts of KCCYSL:MTD were needed to kill the ErbB2-high-expressing FaDu cells. This could be due to the steric hindrance of KCCYSL binding to ErbB2 by the MTD or the lack of a linker sequence such as GSG [11, 12] . However, KWSY:MTD is likely to selectively target the ErbB2-high-expressing cells, such as FaDu and 4T1 cell lines, based on the observation that the killing activity of KWSY:MTD on FaDu was blocked by an anti-ErbB2 antibody or EGF (Fig. 3) . However, it is not yet clear whether An anti-ErbB2 antibody can prevent the KWSY: MTD-induced cell death, which indicates that the function of the MTD is dependent on ErbB2 expression level. In addition, EGF inhibit the KWSY:MTDinduced cell death. This finding is unexpected, as EGF binds to ErbB1 (EGFR) but not to ErbB2 [27] . It provokes to speculate that the binding of EGF to ErbB1 induces the heterodimerization with ErbB2 and spatially blocks the KWSY:MTD binding region on ErbB2 by ErbB1. Alternatively, EGF-induced heterodimerization of ErbB1 and ErbB2 may induce structural changes in ErbB2, and prevent the binding of KWSY:MTD to ErbB2. It would be interesting to define which part of ErbB2 is the KWSY:MTD binding region in future.
As it is not known which part of KWSY:MTD contains the recognition motif for ErbB2, there remains the question of whether KWSY alone can target ErbB2 or not. Additionally, the MTD alone did not induce mitochondrial swelling and may not maintain its helix structure well with only 10 amino acids. Based on these facts, adding a KWSY to the bearing SCID mice were stained with H&E, and images (magnified 40 9 or 400 9 ) were taken and merged using Adobe Photoshop CS5. (E) Livers and kidneys isolated from KWSY:MTD or PBSinjected BalB/C mice were stained with H&E, and images magnified 400 9 were obtained using a light microscope. ***P < 0.001.
MTD seems to not only stabilize the structure of the MTD but also enable a function that recognizes ErbB2. The resulting KWSY:MTD is unable to enter the cell unless it encounters ErbB2 and cannot cause cell death from outside the cell. These findings imply that KWSY:MTD might reduce off-target effects because it cannot directly lyse cells, unlike hybrid peptides that combine lytic peptides and cancer target sequences.
The approach applied herein to develop KWSY: MTD can be adapted to other tumor-targeting motifs to design a hybrid peptide with higher tumor selectivity and fewer off-target effects and lower toxicity. We previously showed that direct coupling of an NRP-1-targeting motif and the MTD (TU17:MTD) successfully suppresses tumor growth; we also demonstrated that the MTD has much better killing activity in TU17:MTD compared to (KLAKLAK) 2 [15] . Thus, we believe that the MTD provides a platform to design a new anticancer therapeutic agent with fewer side effects.
Conventional anticancer drugs slowly induce apoptosis, resulting in transformation and tolerance in cells; this leads to the expectation of low killing efficiency in cancer cells [28, 29] . We observed synergistic or additive effects of combinations using R8:MTD and other anticancer agents in cancer cells (data not shown). As the mechanism of cell death induced by KWSY:MTD is similar to that by R8:MTD, we expect that anticancer effects will be increased when KWSY:MTD and other anticancer agents are used together.
Barriers caused by the microenvironment of cancer and peptidases in the blood are major obstacles to the delivery of peptide-based anticancer drugs [30] [31] [32] . We also observed that the cytotoxicity is decreased when KWSY:MTD is injected into vessels of tumorigenic mice. The peptides may be rapidly inactivated by peptidases and serum elements in the blood. To overcome this problem, we propose modifying KWSY:MTD to a diastereomeric form. Alternatively, we expect local delivery with a catheter will increase anticancer effects.
In conclusion, although KWSY:MTD is still limited by instability in the blood, it displays promise as an anticancer agent. If its limitations can be overcome, it will have a very strong anticancer effect by inducing the necrosis pathway.
